Shots:
The US FDA has accepted the IND application of APG-5918, an oral EED protein inhibitor for the treatment of solid tumors & hematologic malignancies
The FIH, multicenter, open-label P-I study evaluates the safety, tolerability & will determine the DLT, MTD along with the RP2D of APG-5918. The preclinical data of APG-5918 showed potent binding activity with EED protein, in vitro antiproliferative & in vivo antitumor activity
EED protein stimulates the methyltransferase activity of EZH2 (highly expressed in tumor cells) therefore APG-5918 is used as an EED protein inhibitor to act against EZH2 & also can overcome tumor resistance along with delivering complete/durable tumor
Ref: PR Newswire | Image: Ascentage
